The Role of C-Reactive Protein in the Early Prediction of Serious Pancreatic Fistula Development after Pancreaticoduodenectomy

Table 1

Demographic and clinicopathological features of the patients.

Features	Overall ( (%))	Group1 ( (%))	Group 2 ( (%))
(%)	117	9 (7.7)	108 (92.3)
Age (mean ± SD) (year)	60.7 ± 13.3	61 ± 12	60.6 ± 13	0.586
Male/female	71/46	7/2	64/44	0.184
BMI (kg/m^2)	23 ± 3.7	22 ± 3.7	23 ± 3.7	0.186
Preoperative diabetes	29 (24.7)	2 (22.2)	27 (25)	0.286
Pancreatitis history	15 (12.8)	1 (11.1)	14 (12.9)	0.483
Amylase in drain fluid (POD3) (U/mL)^μ	1281.1 ± 5242.4 (41)	946.7 ± 1638.4 (150)	1312.3 ± 5462.2 (34)	0.007
Amylase in drain fluid (POD5) (U/mL)^μ	1395.0 ± 5539.2 (22)	5551.2 ± 120 26.1 (330)	1006.6 ± 4417 (20)	0.0001
Serum amylase (POD3) (U/mL)^μ	37.7 ± 42.6 (22)	60.6 ± 76.4 (30)	35.6 ± 37.9 (22)	0.234
Serum amylase (POD5) (U/mL)^μ	40.6 ± 124.1 (23)	165.9 ± 414.3 (25)	28.8 ± 25.4 (22)	0.145
Quality of pancreas
Soft	34 (29.1)	2	31	0.993
Moderate	46 (39.3)	4	42
Hard	37 (31.6)	3	34
Diameter of pancreatic duct (mm)	4.66 ± 2.15	4.70 ± 2.16	4.65 ± 2.15	0.949
Pathological diagnoses
Adenocarcinoma of the head of the pancreas	60 (51.2)	3 (33.3)	57 (52.7)	0.08
IPMN	30 (25.6)	1 (11.1)	29 (26.8)	0.152
Ampullary adenocarcinoma	10 (8.5)	3 (33.3)	7 (6.48)	0.02
Cholangiocarcinoma	8 (6.8)	1 (11.1)	7 (6.48)	0.482
Malignant neuroendocrine tumor	3 (2.5)	1 (11.1)	2 (1.85)	0.563
Others	6 (5.1)	—	6 (5.55)	0.456
Blood loss (ml)	300 ± 50	350 ± 50	300 ± 50	0.286
Operation time (min)	345.9 ± 70	357.7 ± 73	344.8 ± 69	0.573
Length of hospital stay (day)	11 ± 5	11 ± 5	10 ± 4	0.053
Morbidity	43 (36.7)	9	34	0.0001
Mortality	9 (7.7)	5	4	0.0001

^μMean ± standard deviation (median).